Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment

Fineline Cube Apr 17, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...

Company

Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities

Fineline Cube Apr 16, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...

Company Drug

Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor

Fineline Cube Apr 16, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers

Fineline Cube Apr 16, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...

Company Drug

Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial

Fineline Cube Apr 16, 2024

Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...

Company Drug

Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial

Fineline Cube Apr 16, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...

Policy / Regulatory

EU Set to Investigate China’s Medical Device Procurement Practices Amid Fairness Concerns

Fineline Cube Apr 16, 2024

The European Union (EU) is reportedly gearing up to launch an investigation into medical device...

Company Deals

Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System

Fineline Cube Apr 16, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership...

Company Deals Digital

Vazyme Partners with Yufang Medical to Boost Alzheimer’s Blood Test Sales Online

Fineline Cube Apr 16, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), based in China, has entered into a strategic partnership...

Company Drug

Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC

Fineline Cube Apr 15, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...

Company Deals

89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China

Fineline Cube Apr 15, 2024

U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and...

Company Medical Device

Shanghai Electric Group and Siemens Healthineers Unveil Ultramarine Series Medical Imaging Devices

Fineline Cube Apr 15, 2024

Shanghai Electric Group, a major player in China’s electrical equipment industry, has partnered with Siemens...

Company Deals Digital

JD Healthcare Forges Partnerships with Top Medical Device Firms at CMEF

Fineline Cube Apr 15, 2024

The China International Medical Equipment Fair (CMEF), which took place last week in Shanghai, was...

Policy / Regulatory

FDA Advisory Committee Backs MRD as Accelerated Approval Endpoint for Multiple Myeloma

Fineline Cube Apr 15, 2024

The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has...

Company

I-Mab CEO Outlines Streamlined US Entity’s Focus and Potential for In-Licensing

Fineline Cube Apr 15, 2024

I-Mab (NASDAQ: IMAB), a biopharmaceutical company that recently restructured into separate US and Chinese entities,...

Policy / Regulatory

Hainan Medical Zone Launches ‘Lecheng Global Special Medical Insurance’ for Wider Drug Access

Fineline Cube Apr 15, 2024

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has launched the “Lecheng Global Special...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Approval for Clinical Study of CDK 4/6 Inhibitor Combo in Breast Cancer

Fineline Cube Apr 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company

Blue Shield Biotech Faces Bankruptcy Proceedings After Missing Debt Payments

Fineline Cube Apr 15, 2024

The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield...

Company Medical Device

Roche and Eli Lilly’s Elecsys pTau217 Blood Test Earns FDA Breakthrough Designation for Alzheimer’s Detection

Fineline Cube Apr 15, 2024

The U.S. Food and Drug Administration (FDA) has granted a breakthrough device designation for Elecsys...

Company Drug

3SBio Secures NMPA Approval for Pediatric Thrombopoietin Treatment of ITP

Fineline Cube Apr 15, 2024

3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that it...

Posts pagination

1 … 398 399 400 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.